Apixaban News and Research

RSS
Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

FDA panel votes 9-2 in favor of new blood thinner drug

FDA panel votes 9-2 in favor of new blood thinner drug

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Apixaban superior to warfarin in preventing stroke and systemic embolism

Apixaban superior to warfarin in preventing stroke and systemic embolism

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

New findings of drug recently identified to prevent stroke in patients with AF published in NEJM

New findings of drug recently identified to prevent stroke in patients with AF published in NEJM

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

New era for anticoagulant therapy

New era for anticoagulant therapy

New research focusing on VTE presented at ASH Annual Meeting

New research focusing on VTE presented at ASH Annual Meeting

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Emerging blood thinners to prevent stroke

Emerging blood thinners to prevent stroke

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Venous thromboembolism drugs to experience robust growth by 2019

Venous thromboembolism drugs to experience robust growth by 2019

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Data monitoring committee recommends early termination following impressive results of AVERROES study

Data monitoring committee recommends early termination following impressive results of AVERROES study

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion